Study details
Enrolling now
Assessing Cannabidiol for Anxiety and Depression in Bipolar Disorder
Mclean Hospital
NCT IDNCT05457465ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
25
Study length
about 2.6 years
Ages
18–65
Locations
1 site in MA
About this study
Researchers are testing a custom-formulated high-CBD product to see if it helps with anxiety in adults with bipolar disorder. The trial will last 944 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cannabidiol
PhasePhase 2
DrugCannabidiol
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cannabidiol
Drug routes
oral (Oral Solution)
Endpoints
Secondary: Change in self-reported ratings of depression on the Beck Depression Inventory (BDI)
Body systems
Psychiatry / Mental Health